. . . . . . . "[A sub-analysis of the MIST study: 431 consecutive na�ve patients randomly assigned, based on HCV genotype, to receive either (A) PegIFN?2a 180 ?g/wk plus daily Rbv 800-1200 mg or (B) PegIFN?2b 1.5 ?g/kg/week plus daily Rbv 800-1200 mg, were stratified according to Ishak staging (S) into mild (S0-S2) or moderate (S3, S4) fibrosis and cirrhosis (S5, S6).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:19:04+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .